p27 and Skp2 immunoreactivity and its clinical significance with endocrine and chemo-endocrine treatments in node-negative early breast cancer

Alberto Ravaioli, F. Monti, M. M. Regan, F. Maffini, M. G. Mastropasqua, V. Spataro, M. Castiglione-Gertsch, I. Panzini, L. Gianni, A. Goldhirsch, A. Coates, K. N. Price, B. A. Gusterson, G. Viale

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Background: Low p27 and high Skp2 immunoreactivity are associated with a poor prognosis and other poor prognostic features including resistant phenotypes and antiestrogen drug resistance. We investigated these proteins in two International Breast Cancer Study Group trials studying node-negative early breast cancer. Patients and methods: Trial VIII compared chemotherapy followed by goserelin with either modality alone in premenopausal patients. Trial IX compared chemotherapy followed by tamoxifen with tamoxifen alone in postmenopausal patients. Central Pathology Office assessed p27 and Skp2 expression in the primary tumor by immunohistochemistry among 1631 (60%) trial patients. Results: p27 and Skp2 were inversely related; 13% of tumors expressed low p27 and high Skp2. Low p27 and high Skp2 were associated with unfavorable prognostic factors including larger size and higher grade tumors, absence of estrogen receptor and progesterone receptor, human epidermal growth factor receptor 2 overexpression and high Ki-67 (each P <0.05). Low p27 and high Skp2 were not associated with disease-free survival (P = 0.42 and P = 0.48, respectively). The relative effects of chemo-endocrine versus endocrine therapy were similar regardless of p27 or Skp2. Conclusions: We confirm the association of low p27 and high Skp2 with other poor prognostic features, but found no predictive or prognostic value, and therefore do not recommend routine determination of p27 and Skp2 for node-negative breast cancer.

Original languageEnglish
Pages (from-to)660-668
Number of pages9
JournalAnnals of Oncology
Volume19
Issue number4
DOIs
Publication statusPublished - Apr 2008

Fingerprint

Breast Neoplasms
Tamoxifen
Goserelin
Drug Therapy
Neoplasms
Estrogen Receptor Modulators
Progesterone Receptors
Therapeutics
Drug Resistance
Estrogen Receptors
Disease-Free Survival
Immunohistochemistry
Pathology
Phenotype
Proteins
human ERBB2 protein

Keywords

  • Breast cancer
  • Chemotherapy
  • Hormonal therapy
  • P27
  • Skp2

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

p27 and Skp2 immunoreactivity and its clinical significance with endocrine and chemo-endocrine treatments in node-negative early breast cancer. / Ravaioli, Alberto; Monti, F.; Regan, M. M.; Maffini, F.; Mastropasqua, M. G.; Spataro, V.; Castiglione-Gertsch, M.; Panzini, I.; Gianni, L.; Goldhirsch, A.; Coates, A.; Price, K. N.; Gusterson, B. A.; Viale, G.

In: Annals of Oncology, Vol. 19, No. 4, 04.2008, p. 660-668.

Research output: Contribution to journalArticle

Ravaioli, A, Monti, F, Regan, MM, Maffini, F, Mastropasqua, MG, Spataro, V, Castiglione-Gertsch, M, Panzini, I, Gianni, L, Goldhirsch, A, Coates, A, Price, KN, Gusterson, BA & Viale, G 2008, 'p27 and Skp2 immunoreactivity and its clinical significance with endocrine and chemo-endocrine treatments in node-negative early breast cancer', Annals of Oncology, vol. 19, no. 4, pp. 660-668. https://doi.org/10.1093/annonc/mdm547
Ravaioli, Alberto ; Monti, F. ; Regan, M. M. ; Maffini, F. ; Mastropasqua, M. G. ; Spataro, V. ; Castiglione-Gertsch, M. ; Panzini, I. ; Gianni, L. ; Goldhirsch, A. ; Coates, A. ; Price, K. N. ; Gusterson, B. A. ; Viale, G. / p27 and Skp2 immunoreactivity and its clinical significance with endocrine and chemo-endocrine treatments in node-negative early breast cancer. In: Annals of Oncology. 2008 ; Vol. 19, No. 4. pp. 660-668.
@article{48151b226cce47ae98d5df65d8079465,
title = "p27 and Skp2 immunoreactivity and its clinical significance with endocrine and chemo-endocrine treatments in node-negative early breast cancer",
abstract = "Background: Low p27 and high Skp2 immunoreactivity are associated with a poor prognosis and other poor prognostic features including resistant phenotypes and antiestrogen drug resistance. We investigated these proteins in two International Breast Cancer Study Group trials studying node-negative early breast cancer. Patients and methods: Trial VIII compared chemotherapy followed by goserelin with either modality alone in premenopausal patients. Trial IX compared chemotherapy followed by tamoxifen with tamoxifen alone in postmenopausal patients. Central Pathology Office assessed p27 and Skp2 expression in the primary tumor by immunohistochemistry among 1631 (60{\%}) trial patients. Results: p27 and Skp2 were inversely related; 13{\%} of tumors expressed low p27 and high Skp2. Low p27 and high Skp2 were associated with unfavorable prognostic factors including larger size and higher grade tumors, absence of estrogen receptor and progesterone receptor, human epidermal growth factor receptor 2 overexpression and high Ki-67 (each P <0.05). Low p27 and high Skp2 were not associated with disease-free survival (P = 0.42 and P = 0.48, respectively). The relative effects of chemo-endocrine versus endocrine therapy were similar regardless of p27 or Skp2. Conclusions: We confirm the association of low p27 and high Skp2 with other poor prognostic features, but found no predictive or prognostic value, and therefore do not recommend routine determination of p27 and Skp2 for node-negative breast cancer.",
keywords = "Breast cancer, Chemotherapy, Hormonal therapy, P27, Skp2",
author = "Alberto Ravaioli and F. Monti and Regan, {M. M.} and F. Maffini and Mastropasqua, {M. G.} and V. Spataro and M. Castiglione-Gertsch and I. Panzini and L. Gianni and A. Goldhirsch and A. Coates and Price, {K. N.} and Gusterson, {B. A.} and G. Viale",
year = "2008",
month = "4",
doi = "10.1093/annonc/mdm547",
language = "English",
volume = "19",
pages = "660--668",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "NLM (Medline)",
number = "4",

}

TY - JOUR

T1 - p27 and Skp2 immunoreactivity and its clinical significance with endocrine and chemo-endocrine treatments in node-negative early breast cancer

AU - Ravaioli, Alberto

AU - Monti, F.

AU - Regan, M. M.

AU - Maffini, F.

AU - Mastropasqua, M. G.

AU - Spataro, V.

AU - Castiglione-Gertsch, M.

AU - Panzini, I.

AU - Gianni, L.

AU - Goldhirsch, A.

AU - Coates, A.

AU - Price, K. N.

AU - Gusterson, B. A.

AU - Viale, G.

PY - 2008/4

Y1 - 2008/4

N2 - Background: Low p27 and high Skp2 immunoreactivity are associated with a poor prognosis and other poor prognostic features including resistant phenotypes and antiestrogen drug resistance. We investigated these proteins in two International Breast Cancer Study Group trials studying node-negative early breast cancer. Patients and methods: Trial VIII compared chemotherapy followed by goserelin with either modality alone in premenopausal patients. Trial IX compared chemotherapy followed by tamoxifen with tamoxifen alone in postmenopausal patients. Central Pathology Office assessed p27 and Skp2 expression in the primary tumor by immunohistochemistry among 1631 (60%) trial patients. Results: p27 and Skp2 were inversely related; 13% of tumors expressed low p27 and high Skp2. Low p27 and high Skp2 were associated with unfavorable prognostic factors including larger size and higher grade tumors, absence of estrogen receptor and progesterone receptor, human epidermal growth factor receptor 2 overexpression and high Ki-67 (each P <0.05). Low p27 and high Skp2 were not associated with disease-free survival (P = 0.42 and P = 0.48, respectively). The relative effects of chemo-endocrine versus endocrine therapy were similar regardless of p27 or Skp2. Conclusions: We confirm the association of low p27 and high Skp2 with other poor prognostic features, but found no predictive or prognostic value, and therefore do not recommend routine determination of p27 and Skp2 for node-negative breast cancer.

AB - Background: Low p27 and high Skp2 immunoreactivity are associated with a poor prognosis and other poor prognostic features including resistant phenotypes and antiestrogen drug resistance. We investigated these proteins in two International Breast Cancer Study Group trials studying node-negative early breast cancer. Patients and methods: Trial VIII compared chemotherapy followed by goserelin with either modality alone in premenopausal patients. Trial IX compared chemotherapy followed by tamoxifen with tamoxifen alone in postmenopausal patients. Central Pathology Office assessed p27 and Skp2 expression in the primary tumor by immunohistochemistry among 1631 (60%) trial patients. Results: p27 and Skp2 were inversely related; 13% of tumors expressed low p27 and high Skp2. Low p27 and high Skp2 were associated with unfavorable prognostic factors including larger size and higher grade tumors, absence of estrogen receptor and progesterone receptor, human epidermal growth factor receptor 2 overexpression and high Ki-67 (each P <0.05). Low p27 and high Skp2 were not associated with disease-free survival (P = 0.42 and P = 0.48, respectively). The relative effects of chemo-endocrine versus endocrine therapy were similar regardless of p27 or Skp2. Conclusions: We confirm the association of low p27 and high Skp2 with other poor prognostic features, but found no predictive or prognostic value, and therefore do not recommend routine determination of p27 and Skp2 for node-negative breast cancer.

KW - Breast cancer

KW - Chemotherapy

KW - Hormonal therapy

KW - P27

KW - Skp2

UR - http://www.scopus.com/inward/record.url?scp=41549123554&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41549123554&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdm547

DO - 10.1093/annonc/mdm547

M3 - Article

C2 - 18272916

AN - SCOPUS:41549123554

VL - 19

SP - 660

EP - 668

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 4

ER -